Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua J Meeks

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
European Urology|October 1, 2024
FGFR Inhibition in Urothelial CarcinomaRoger Li, Joshua Linscott, James W F Catto, et al.
Journal of Oncology Practice|August 11, 2017
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline SummarySam S Chang, Bernard H Bochner, Roger Chou, et al.
The Journal of Urology|May 1, 2017
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO GuidelineSam S Chang, Bernard H Bochner, Roger Chou, et al.
Science Advances|January 2, 2026
STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell-induced CD4+ T cell toleranceJoseph R Podojil, Andrew C Cogswell, Tobias Neef, et al.
Nature Reviews. Urology|March 28, 2023
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
Nature Reviews. Urology|May 22, 2023
Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
Frontiers in Immunology|July 3, 2020
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting StrategiesLijie Zhai, April Bell, Erik Ladomersky, et al.
Frontiers in Immunology|September 5, 2022
Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapyJoseph R Podojil, Andrew C Cogswell, Ming-Yi Chiang, et al.
Urology|September 1, 2022
An Evaluation of Peer-Rated Surgical Skill and its Relationship With Detrusor Muscle Sampling in Transurethral Resection of Bladder TumorMinh N Pham, Oliver S Ko, Reiping Huang, et al.
Journal for Immunotherapy of Cancer|July 16, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancerMatthew D Galsky, Arjun V Balar, Peter C Black, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
European Urology|October 1, 2024
FGFR Inhibition in Urothelial CarcinomaRoger Li, Joshua Linscott, James W F Catto, et al.
Journal of Oncology Practice|August 11, 2017
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline SummarySam S Chang, Bernard H Bochner, Roger Chou, et al.
The Journal of Urology|May 1, 2017
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO GuidelineSam S Chang, Bernard H Bochner, Roger Chou, et al.
Science Advances|January 2, 2026
STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell-induced CD4+ T cell toleranceJoseph R Podojil, Andrew C Cogswell, Tobias Neef, et al.
Nature Reviews. Urology|March 28, 2023
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
Nature Reviews. Urology|May 22, 2023
Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
Frontiers in Immunology|July 3, 2020
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting StrategiesLijie Zhai, April Bell, Erik Ladomersky, et al.
Frontiers in Immunology|September 5, 2022
Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapyJoseph R Podojil, Andrew C Cogswell, Ming-Yi Chiang, et al.
Urology|September 1, 2022
An Evaluation of Peer-Rated Surgical Skill and its Relationship With Detrusor Muscle Sampling in Transurethral Resection of Bladder TumorMinh N Pham, Oliver S Ko, Reiping Huang, et al.
Journal for Immunotherapy of Cancer|July 16, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancerMatthew D Galsky, Arjun V Balar, Peter C Black, et al.
Pageof 21